USPTO Grants Acurx Pharmaceuticals Patent For Gut Health-Boosting CDI Treatment
Acurx gains new patent for ibezapolstat, advancing Phase 3 trials for treating C. difficile infections.
Breaking News
Jul 18, 2024
Mrudula Kulkarni

Acurx Pharmaceuticals, Inc., a biopharmaceutical company in the advanced stages of developing new small molecule antibiotics for challenging bacterial infections, announced today that the United States Patent and Trademark Office (USPTO) granted a new patent on July 16, 2024. This patent pertains to ibezapolstat, which is designed to treat C. difficile Infection (CDI) while reducing its recurrence and enhancing gut microbiome health. This patent is the latest addition to Acurx's series of granted patents and pending applications aimed at safeguarding their innovative antimicrobial technologies.
Robert J. DeLuccia, Executive Chairman of Acurx, said in a statement: "This patent is very important and timely as ibezapolstat continues to demonstrate previously unexpected and favorable effects on the gut microbiome while at the same time curing the C. difficile bacterial infection and preventing recurrent infection." He further added: "As we continue to prepare for initiation of our Phase 3 clinical program, we expect this feature of ibezapolstat's selective mechanism of action to be further demonstrated and to be an important competitive advantage over currently available antibiotics by reducing the recurrence of the infection. This could have a dramatically favorable effect on patient outcomes and on reducing downstream healthcare costs."
David P. Luci, President & CEO of Acurx, also added, "This latest patent is part of our company's pivotal product, ibezapolstat, which is a two-dimensional antibiotic to cure infections clinically comparable to marketed antibiotics while restoring the microbiome and preventing reinfections which is unusually positive for CDI antibiotics.
Acurx recently announced a successful FDA End-of-Phase 2 Meeting, confirming Phase 3 readiness for ibezapolstat in treating C. difficile Infection. The FDA has agreed on the essential aspects to proceed with the international Phase 3 clinical trial program and has also endorsed the comprehensive non-clinical and clinical development plan required for the New Drug Application (NDA) submission for marketing approval. The company is actively planning to advance ibezapolstat into international Phase 3 trials for CDI treatment and is preparing to request guidance for initiating clinical trials in the European Union, the United Kingdom, Japan, and Canada.